Guobang Pharma Future Growth
Future criteria checks 2/6
Guobang Pharma is forecast to grow earnings and revenue by 22.6% and 13.8% per annum respectively. EPS is expected to grow by 19.1% per annum. Return on equity is forecast to be 12.2% in 3 years.
Key information
22.6%
Earnings growth rate
19.1%
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | 13.8% |
| Future return on equity | 12.2% |
| Analyst coverage | Low |
| Last updated | 22 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 7,572 | 1,148 | N/A | 1,191 | 2 |
| 12/31/2025 | 7,306 | 1,110 | 908 | 1,515 | 3 |
| 12/31/2024 | 5,916 | 810 | 186 | 612 | 2 |
| 9/30/2024 | 5,714 | 702 | 62 | 539 | N/A |
| 6/30/2024 | 5,432 | 660 | -345 | 235 | N/A |
| 3/31/2024 | 5,278 | 617 | -495 | 227 | N/A |
| 12/31/2023 | 5,349 | 612 | -232 | 517 | N/A |
| 9/30/2023 | 5,661 | 689 | -466 | 416 | N/A |
| 6/30/2023 | 5,827 | 783 | -78 | 839 | N/A |
| 3/31/2023 | 5,955 | 915 | 276 | 1,159 | N/A |
| 12/31/2022 | 5,721 | 921 | 214 | 1,017 | N/A |
| 9/30/2022 | 5,405 | 906 | 15 | 486 | N/A |
| 6/30/2022 | 4,966 | 823 | -576 | -177 | N/A |
| 3/31/2022 | 4,539 | 721 | -497 | -126 | N/A |
| 12/31/2021 | 4,505 | 706 | -624 | -176 | N/A |
| 9/30/2021 | 4,273 | 694 | -481 | 39 | N/A |
| 6/30/2021 | 4,317 | 741 | -110 | 444 | N/A |
| 3/31/2021 | 4,449 | 834 | -59 | 612 | N/A |
| 12/31/2020 | 4,206 | 810 | 246 | 768 | N/A |
| 12/31/2019 | 3,802 | 315 | -164 | 441 | N/A |
| 12/31/2018 | 3,279 | 211 | 378 | 542 | N/A |
| 12/31/2017 | 2,905 | 178 | N/A | 148 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 605507's forecast earnings growth (22.6% per year) is above the savings rate (2.8%).
Earnings vs Market: 605507's earnings (22.6% per year) are forecast to grow slower than the CN market (26.2% per year).
High Growth Earnings: 605507's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 605507's revenue (13.8% per year) is forecast to grow slower than the CN market (13.9% per year).
High Growth Revenue: 605507's revenue (13.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 605507's Return on Equity is forecast to be low in 3 years time (12.2%).